Tag Archives: Chad Mirkin

RIP (rest in peace) Sir Fraser Stoddart, nanotechnology pioneer

I received (via email and it’s also here) a January 2, 2025 Northwestern University news release by Megan Fellman announcing Sir Fraser Stoddart’s (also known as, J. Fraser Stoddart) death on December 30, 2024, Note: Links have been removed,

Sir Fraser Stoddart, a pioneer in nanoscience, dies at 82

Stoddart received the 2016 Nobel Prize in Chemistry for work on molecular machines

EVANSTON, Ill. — Nobel laureate Sir Fraser Stoddart, a Board of Trustees Professor at Northwestern University, died Dec. 30 [2024]. He was 82.

Stoddart, a pioneer in the fields of nanoscience and organic chemistry, was an outsized figure on the Evanston campus and on campuses he visited around the globe. By introducing an additional type of bond — the mechanical bond — into chemical compounds, Stoddart became one of the
few chemists to have opened a new field of chemistry during the past 30 years.

His work on molecular recognition and self-assembly and his subsequent introduction of template-directed routes to mechanically interlocked molecules dramatically changed the way chemists make soft materials.

Throughout his long career of research and teaching, Stoddart mentored a diverse group of more than 500 graduate and postdoctoral students from around the world. Gregarious and thoughtful, he particularly cherished this work and the resulting relationships, many of them lifelong.

“Fraser was a giant in fields of nanoscience and organic chemistry, but his influence was equally impressive in the classrooms and labs on our campus,” said Northwestern President Michael Schill. “He was incredibly generous with his time and mentored so many students and
faculty, helping pave important new paths of inquiry and discovery. His impact on our university — and the world — was enormous.”

Omar Faha, the Charles E. and Emma H. Morrison Professor in Chemistry at Northwestern and chair of the department, said beyond his scientific brilliance, Stoddart was a steadfast friend and mentor, always generous with his time, wisdom and encouragement. “His contributions to our community went far beyond his accolades, as he supported and elevated each of us through his boundless energy and spirit.”

Since 2023, Stoddart was the Chair Professor of Chemistry at the University of Hong Kong.

A Northwestern Nobel

Stoddart received the Nobel Prize in Chemistry in 2016, along with Jean-Pierre Sauvage and Bernard L. Feringa, “for the design and synthesis of molecular machines.” The Royal Swedish Academy of Sciences credited them with developing “molecules with controllable movements, which can perform a task when energy is added.”

“The development of computing demonstrates how the miniaturization of technology can lead to a revolution,” the academy said in its announcement. “The 2016 Nobel Laureates in Chemistry have miniaturized machines and taken chemistry to a new dimension.”

For his part, Stoddart was awarded the prize because, the academy said, in 1991 he developed a rotaxane. He threaded a molecular ring onto a thin molecular axle and demonstrated that the ring was able to move along the axle. Among his developments based on rotaxanes are a molecular lift, a molecular muscle and a molecule-based computer chip.

Stoddart’s introduction of the mechanical bond, which has led to the fabrication of artificial molecular switches and motors, has been responsible for putting chemists at the forefront of the burgeoning field of molecular nanotechnology, with implications ranging all the way from information technology to health care.

Upon becoming the second Nobel Prize winner from Northwestern’s department of chemistry, Stoddart expressed his appreciation for the University’s academic community.

“I also share this recognition with my students, postdoctoral fellows and colleagues,” he said. “Northwestern is a special place, where everyone does science in a collaborative way. It happens seamlessly here. If you don’t have the expertise, you can find it, and people step forward without being asked. It is well known that we hunt in packs at Northwestern.”

Said Adrian Randolph, dean of the Weinberg College of Arts and Sciences at Northwestern: “Sir Fraser brought a sparkling creativity, an indefatigable work ethic, a global perspective and a sharp wit that often reflected his broad interests and his belief in the value of a liberal arts education to his work and life. His scientific findings and ambition will continue to reverberate through the College and University. He will be sorely missed.”

Scientific achievements

Stoddart’s achievements include raising the bar for molecular electronics. For example, he used molecules on the nanoscale as the tiniest of switches, which have been incorporated into the densest of memory chips in a device that can hold the Declaration of Independence but is only the size of a white blood cell. He also gave practical expression to artificial molecular switches using nanovalves planted on the surfaces of mesoporous glass nanoparticles to create controllable and targeted drug delivery systems for the treatment of cancer and other degenerative diseases.

In 2007, The Sunday Times in the U.K. wrote that Stoddart “is to nanotechnology what J.K. Rowling is to children’s literature.”

That same year, he was appointed by Her Majesty Queen Elizabeth II as a Knight Bachelor in her 2007 New Year’s Honours List for his services to “Chemistry and Molecular Nanotechnology.”

“After being knighted, the queen and I had a short exchange, and I concluded she had her wits about her and had done her homework,” Stoddart recalled in a 2022 interview with Northwestern Now after the Queen’s passing. He was one of three to receive knighthoods at a ceremony that included other significant honors. “The main subject of conversation among us afterwards was, ‘How did she know so much about me?’”

A native of Edinburgh, Scotland, Stoddart also received the Royal Medal in 2010 from His Royal Highness the Duke of Edinburgh at the Royal Society of Edinburgh (RSE), Scotland’s national academy of arts and sciences.

A common theme of Stoddart’s research was the quest for a better fundamental understanding of self-assembly and molecular recognition processes in chemical systems. He worked for more than three decades on using this growing understanding to develop template-directed protocols that rely upon such processes to create artificial molecular machines. Stoddart’s philosophy of transferring concepts from biology into chemistry was behind his bottom-up approach to the construction of integrated nanosystems.

“My research on mechanically interlocked molecules, which has taken the field of supramolecular chemistry, i.e., chemistry beyond the molecule, back into the molecular domain, heralds a game-changer for molecular nanotechnology,” Stoddart once said.

Northwestern nanoscientist Chad Mirkin said hiring Stoddart was one of the best moves the University made.

“He is a big part of the ‘rise of Northwestern’ story,” said Mirkin, the George B. Rathmann Professor of Chemistry and a professor of medicine, chemical and biological engineering, biomedical engineering, and materials science and engineering. “Generous with his time, intellect and support, he made Northwestern and everyone around him better.”

Other honors and activities

Stoddart was elected to Fellowship of the American Academy of Arts and Sciences in 2012, membership of the National Academy of Sciences in 2014, foreign membership of the Chinese Academy of Sciences in 2017 and Fellowship of the National Academy of Inventors in 2019.

During his career, Stoddart received many other prestigious national and international awards and honors. They include being elected an Honorary Fellow of both the RSE and the Royal Society of Chemistry (RSC) and receiving the Davy Medal from the Royal Society of London, the national
academy of science of the United Kingdom and the Commonwealth, of which he was also a Fellow. Other awards include the China International Science and Technology Cooperation Award, the Nagoya Gold Medal in Organic Chemistry, the American Chemical Society’s Arthur C. Cope Award, the Feynman Prize in Nanotechnology, the King Faisal International Prize in Science, the Tetrahedron Prize for Creativity in Organic Chemistry, the Albert Einstein World Award of Science and the RSC’s Centenary Prize.

Stoddart served on the international advisory boards of numerous journals, including Chemistry World, Organic Letters and ChemPlusChem. He published more than 1,300 scientific papers and trained more than 500 graduate and postdoctoral students during an academic career that spanned five decades.

Northwestern professor Will Dichtel was one of Stoddart’s postdoctoral researchers.

“Underlying his considerable accolades was an endlessly supportive and caring mentor, colleague and friend. I was fortunate to learn from him first as a postdoctoral researcher at UCLA, just before he moved to Northwestern, where he encouraged my creativity and courage to tackle big scientific problems,” said Dichtel, the Robert L. Letsinger Professor of Chemistry.

“Later, in my independent career, he continued to support, encourage and challenge me. Fraser played this role to hundreds of scientists around the world. We will all miss him dearly and take this sad occasion to reflect upon and acknowledge his considerable personal and scientific
impact.”

Prior to Northwestern

Before joining the Northwestern faculty, Stoddart was Fred Kavli Chair in Nanosystems Sciences at the University of California at Los Angeles and director of the California NanoSystems Institute. He came to UCLA in 1997 from England’s University of Birmingham, where he had been a professor of organic chemistry since 1990 and had headed the university’s School of Chemistry since 1993.

Born in Edinburgh in 1942, Stoddart received his Bachelor of Science (1964), Ph.D. (1966) and D.Sc. (1980) degrees from the University of Edinburgh.

In 1967, he moved to Queen’s University in Ontario, Canada, where he was a National Research Council postdoctoral fellow and then, in 1970, to England’s University of Sheffield, where he was first an Imperial Chemical Industries (ICI) research fellow before becoming a faculty lecturer (assistant professor) in chemistry. After spending a three-year “secondment” (1978 to 1981) at the ICI Corporate Laboratory in Runcorn, England, he returned full time to the University of Sheffield,
where he was promoted to a readership (associate professorship). He moved to the University of Birmingham in 1990 to take up the Chair of Organic Chemistry.

Survivors include his two daughters, Fiona McCubbin of Belmont, Massachusetts, and Alison Stoddart of Cambridge, UK, and five grandchildren. His wife, Norma, preceded him in death.

I have an October 6, 2016 post for when the 2016 Nobel Prize in Chemistry was announced but I find a February 19, 2018 posting “2016 Nobel prize winner introduces anti-aging skincare line” about Stoddart’s then latest venture more intriguing.

2024 Kavli Prize Laureates: in the fields of astrophysics, nanoscience and neuroscience

The Kavli Prize has yet to acquire the lustre of a Nobel Prize (first awarded in 1901 as per its Wikipedia entry). By comparison the Kavli Prize is relatively new (established in 2005 as per its Wikipedia entry) but it appears to be achieving big deal status in the US.

This year’s crop of prize winners was listed in a June 12, 2024 Kavli Foundation news release on EurekAlert,

Eight scientists from three countries are honored for their research that has broadened our understanding of the big, the small and the complex.

June 12, 2024 (Oslo, Norway) — The Norwegian Academy of Science and Letters today announced the 2024 Kavli Prize Laureates in the fields of astrophysics, nanoscience and neuroscience. Eight scientists from three countries are honored for their research that has broadened our understanding of the big, the small and the complex. The laureates in each field will share $1 million USD. 

The 2024 Kavli Prizes recognize groundbreaking science for the discovery and characterization of extra-solar planets and their atmospheres; foundational research integrating synthetic nanoscale materials for biomedical use; and the localization of areas in the brain specialized for face recognition and processing.  

The 2024 Kavli Prize Laureates are:  

  • Kavli Prize in Astrophysics: David Charbonneau (Canada/USA) and Sara Seager (Canada/USA) 
  • Kavli Prize in Nanoscience: Robert S. Langer (USA), Armand Paul Alivisatos (USA) and Chad A. Mirkin (USA) 
  • Kavli Prize in Neuroscience: Nancy Kanwisher (USA), Winrich Freiwald (Germany), and Doris Tsao (USA) 

“The Kavli Prize 2024 honors outstanding researchers doing fundamental science that moves the world forward. They are exploring planets outside our solar system; they have broadened the scientific field of nanoscience towards biomedicine; and they are adding to our understanding of the neurological basis of face recognition,” said Lise Øvreås, president at The Norwegian Academy of Science and Letters.  

Astrophysics: Searching for life beyond Earth  

The 2024 Kavli Prize in Astrophysics honors Sara Seager and David Charbonneau for discoveries of exoplanets and the characterization of their atmospheres. They pioneered methods for the detection of atomic species in planetary atmospheres and the measurement of their thermal infrared emission, setting the stage for finding the molecular fingerprints of atmospheres around both giant and rocky planets. Their contributions have been key to the enormous progress seen in the last 20 years in the exploration of myriad exo-planets.  

“Humans have always looked towards the stars for discoveries. The pivotal research conducted by Seager and Charbonneau has been an important first step towards finding new planets and strong evidence of life elsewhere in the universe,” remarked Viggo Hansteen, Chair of the Astrophysics Committee.  

David Charbonneau led the team that used the transit method to discover a giant exoplanet (HD 209458b). He pioneered the application of space-based observatories to perform the first studies of the atmosphere of giant extrasolar planets. This new method measures the tiny amount of light blocked by such a planet as it passes in front of its host star. Charbonneau has also used the transit method to study exoplanetary atmospheres, measuring molecular spectra using both filtered starlight and infrared emission from the planets themselves. He demonstrated these two approaches with observations from the Hubble Space Telescope in 2002 and the Spitzer Space Telescope three years later.  

Sara Seager pioneered the theoretical study of planetary atmospheres and predicted the presence of atomic and molecular species detectable by transit spectroscopy, most notably the alkali gases. She predicted how transits could be used to measure atomic and molecular characteristics in exoplanetary atmospheres, which is crucial for identifying biomarkers – signs of life. Seager made outstanding contributions to the understanding of planets with masses below that of Neptune. She also carried out extensive research on starshades – enormous petal-like structures designed to shield space observatories from the glare of a faraway Sun-like star – and was among the first to recognize their importance in detecting and characterizing the faint light from any Earth-like planet orbiting the star. 

Nanoscience: Integrating nanomaterials for biomedical advances 

The 2024 Kavli Prize in Nanoscience honors Robert S. Langer, Armand Paul Alivisatos and Chad A. Mirkin who each revolutionized the field of nanomedicine by demonstrating how engineering nanoscale materials can advance biomedical research and application. Their discoveries contributed foundationally to the development of therapeutics, vaccines, bioimaging and diagnostics.   

“The three scientists, Langer, Alivisatos and Mirkin, have broadened the scientific field of nanoscience, building from fundamental research. By scientific curiosity they have become inventors for the future of nanoscience and biomedicine,” stated Bodil Holst, Chair of the Nanoscience Committee.  

Robert S. Langer was the first to develop nano-engineered materials that enabled the controlled release, or regular flow, of drug molecules. This capability has had an immense impact for the treatment of a range of diseases, such as aggressive brain cancer, prostate cancer and schizophrenia. His work also showed that tiny particles, containing protein antigens, can be used in vaccination, and was instrumental in the development of the delivery of mRNA vaccines. 

Armand Paul Alivisatos demonstrated that semiconductor nanocrystals, or quantum dots (nanoparticles that possess bright, size-dependent light-emitting properties), can be used as multicolor probes in bioimaging. Essential to this achievement was the synthesis of biocompatible nanocrystals. Semiconductor nanocrystals became the basis for the widely used research and diagnostic tools such as live cell tracking, labelling and in vivo imaging. 

Chad A. Mirkin engineered spherical nucleic acids (SNA) using a gold nanoparticle as the core, and a cloud of radially distributed DNA or RNA strands as the shell. He was then able to show how SNAs can be combined to create larger structures and how they can be used in biodiagnostics. His discovery led to the development of fast, automated point-of-care medical diagnostic systems.  

Neuroscience: Understanding recognition of faces 

The 2024 Kavli Prize in Neuroscience honors Nancy Kanwisher, Doris Tsao and Winrich Freiwald for the discovery of a specialized system within the brain to recognize faces. Their discoveries have provided basic principles of neural organization and made the starting point for further research on how the processing of visual information is integrated with other cognitive functions.  

“Kanwisher, Freiwald and Tsao together discovered a localized and specialized neocortical system for face recognition. Their outstanding research will ultimately further our understanding of recognition not only of faces, but objects and scenes,” commented Kristine Walhovd, Chair of the Neuroscience Committee.  

Nancy Kanwisher was the first to prove that a specific area in the human neocortex is dedicated to recognizing faces, now called the fusiform face area. Using functional magnetic resonance imaging (fMRI) she found individual differences in the location of this area and devised an analysis technique to effectively localize specialized functional regions in the brain. This technique is now widely used and applied to domains beyond the face recognition system.  

Elaborating on Kanwisher’s findings, Winrich Freiwald and Doris Tsao studied macaques and mapped out six distinct brain regions, known as the face patch system, including these regions’ functional specialization and how they are connected. By recording the activity of individual brain cells, they revealed how cells in some face patches specialize in faces with particular views.  

Tsao proceeded to identify how the face patches work together to identify a face, through a specific code that enables single cells to identify faces by assembling information of facial features. For example, some cells respond to the presence of hair, others to the distance between the eyes. 

Freiwald uncovered that a separate brain region, called the temporal pole, accelerates our recognition of familiar faces, and that some cells are selectively responsive to familiar faces. 

There’s a video of the official 2024 Kavli Prize announcement which despite the Kavli Foundation being headquartered in California, US, was held (as noted in the news release) at the Norwegian Academy of Science and Letters where the organization’s president, Lise Øvreås, revealed the 2024 Kavli Prize laureates..(I’ll get back to that choice of location.)

The 2024 Kavli Prize in Nanoscience

There are many posts here featuring work from Robert S. Langer (or Robert Langer), Armand Paul Alivisatos (or Paul Alivisatos or A. Paul Alivisatos) and Chad A. Mirkin (or Chad Mirkin).

Northwestern University (Chicago, Illinois) issued a June 12, 2024 news release (also received via email) by Maria Paul that provides a few more details about the nanoscience winners (main focus: Chad Mirkin), the prize, and the Kavli Foundation. Note: A link has been removed,

Northwestern University nanoscientist Chad Mirkin has been awarded The 2024 Kavli Prize in Nanoscience by The Norwegian Academy of Science and Letters. Mirkin is the first Northwestern scientist to receive the prestigious award.

Mirkin is recognized for his discovery of spherical nucleic acids (SNAs), nanostructures comprised of a nanoparticle core and a shell of radially distributed DNA or RNA strands. These globular forms of nucleic acids have become the cornerstones of the burgeoning fields of nanomedicine and colloidal crystal engineering with DNA. They allow scientists to construct new forms of matter using particle “atoms” as the basic building blocks and DNA “bonds” as particle interconnects, and they are the basis for powerful tools that allow researchers and clinicians to track and treat disease in new ways. In particular, SNAs have led to the development of fast, automated point-of-care medical diagnostic systems and new experimental drugs for treating many forms of cancer, neurological disorders, and diseases of the skin.

Mirkin is one of three laureates in nanoscience recognized by The Norwegian Academy for revolutionizing the field of nanomedicine by demonstrating how engineering nanoscale structures can advance biomedical research and application. The other two are Robert Langer of the Massachusetts Institute of Technology and Paul Alivisatos of the University of Chicago [emphasis mine]. The scientists’ discoveries “contributed foundationally to the development of therapeutics, vaccines, bioimaging and diagnostics,” The Norwegian Academy said in a release. They will share the $1 million award.

“When I first found out I won The Kavli Prize, there was both excitement but also relief, because I consider Northwestern to be the ultimate center for nanotechnology research,” Mirkin said. “To be recognized with this award, along with my incredible co-awardees, was great validation of what we’ve been trying to do at Northwestern. While I’m proud of what we’ve accomplished, the best is yet to come.”

The laureates will be awarded the prize on Sept. 3 during a ceremony in Oslo, Norway, presided over the by The Royal Family. The Kavli Prizes thus far have honored 65 scientists from 13 countries. Ten laureates received the Nobel Prize after receiving The Kavli Prize. [emphasis mine]

“I am thrilled for Chad, for the International Institute for Nanotechnology and for Northwestern,” Northwestern President Michael Schill said. “Chad has earned this prestigious and influential award in a pathbreaking area of science that is aligned with two of the University’s key priorities — to lead in decarbonization, renewable energy and sustainability, and innovating in the biosciences to help prolong lives and make the world a healthier place.

“Through groundbreaking research and hard work, Chad and his team have made Northwestern a leading center for nanotechnology research and investment. The fact that he is sharing this award with President Alivisatos at U of C further emphasizes how the Chicago area has become an international hub for nano research.”

The vision for The Kavli Prize comes from Fred Kavli, a Norwegian-American entrepreneur and philanthropist [emphasis mine] who turned his lifelong fascination with science into a lasting legacy for recognizing scientific breakthroughs and supporting basic research.

Since the first awards in 2008, The Kavli Prize has recognized innovative scientific research — from the discovery of CRISPR-Cas9 to the detection of gravitational waves — transforming our understanding of the big, the small and the complex.

Mirkin’s discovery of SNAs has far-reaching implications for biology and medicine. SNAs, which have no known natural equivalents, interact uniquely with living systems compared to nucleic acids of other forms. Mirkin was the first to synthesize SNAs and elucidate the distinctive chemical and physical properties that underpin their use in transformative techniques and technologies in medicine and the life sciences. This work has led to the development of the first commercialized molecular medical diagnostic systems of the modern nanotechnology era, such as the Food and Drug Administration-cleared Verigene System, used in over half of the world’s top hospitals to detect diseases with high sensitivity and selectivity.

Illinois Gov. JB Pritzker praised Mirkin for his extraordinary contributions to the field of nanotechnology and how his innovations have helped find solutions to some of society’s biggest challenges.

“Academic institutions in Chicago and across Illinois have become the biggest drivers in nanoscience and technology over the last three decades,” Pritzker said. “Chad Mirkin and his Northwestern colleagues have made outstanding scientific discoveries that change how we view the world around us.”

In 1996, Mirkin created the first SNAs with DNA shells on gold nanoparticle cores. Over the years, he has developed numerous other types of SNAs with other shells and cores, including proteins, liposomes and FDA-approved materials, as well as core-less, hollow structures composed entirely of nucleic acids. These cores impart unique properties to the SNAs, such as optical and magnetic characteristics, while also serving as scaffolds to densely arrange the oligonucleotides, which participate in binding. This dense arrangement gives rise to the novel functional properties that differentiate SNAs from the natural linear and two-dimensional nucleic acids and make them particularly effective in interacting with certain biological structures within cells and tissues. SNAs, unlike conventional DNA and RNA, are naturally taken up by cells without the need for toxic, positively charged co-carriers, making them highly effective in RNA interference (RNAi), antisense gene regulation, and gene editing pathways.

Mirkin’s pioneering work on SNAs has also advanced the development of immunotherapeutics, structures capable of stimulating a patient’s immune response to fight both infectious diseases and certain forms of cancer. Using SNAs, Mirkin has pioneered the concept of rational vaccinology, where he demonstrated that the structure of a vaccine, rather than the components alone, is crucial for dictating its therapeutic effectiveness. This insight and these “structural nanomedicines” have opened new possibilities for developing curative treatments by rearranging known components into more effective structures at the nanoscale. Mirkin founded Flashpoint Therapeutics to commercialize these innovations, focusing on nucleic acid-based nanostructure cancer vaccines. Mirkin also invented the first SNA-based antiviral vaccine, using COVID-19 as a model. These SNAs, featuring the spike protein’s RBD subunit in the core, achieved a 100% survival rate in humanized mice challenged with the live virus. These structures and concepts for designing such vaccines are poised to move vaccine development beyond the current mRNA vaccines.

In addition, Mirkin invented dip-pen nanolithography, initially a technique for molecular writing with nanometer-scale precision that has evolved into a powerful platform for tip-based materials synthesis that, when combined with artificial intelligence, is revolutionizing how materials important for many sectors, especially clean energy, are discovered. Dip-pen nanolithography, which has spurred subsequent techniques that now use tens of millions of tiny tips to rapidly synthesize materials to be explored for such purposes, was recognized by National Geographic as one of the “top 100 scientific discoveries that changed the world.” These innovations are being commercialized by Mattiq, Inc., another venture-backed company Mirkin cofounded. Mirkin and his students also invented high-area rapid printing, an additive manufacturing technology, that is being commercialized by Azul 3D and being used to disrupt the microelectronics and optical lens industries.

Mirkin’s research has progressed SNA drugs through seven human clinical trials so far for treating various cancers, including glioblastoma multiforme and Merkel cell carcinoma. One SNA drug has shown remarkable potential in stimulating the immune system, proving effective in models of breast, colorectal and bladder cancers, lymphoma and melanoma. This drug has achieved complete tumor elimination in a subset of patients with Merkel cell carcinoma during Phase 1b/2 clinical trials, earning FDA fast-track and orphan drug status. It was recently licensed to Bluejay Therapeutics to treat hepatitis.

In 2000, Mirkin founded the International Institute for Nanotechnology (IIN) at Northwestern University, which he also directs. Research at the IIN has led to over 2,000 new commercial products sold globally and the creation of more than 40 startup companies. The IIN has collectively brought together over $1.2 billion to support research, education and infrastructure at Northwestern since its inception.

Mirkin is the George B. Rathmann Professor of Chemistry and a professor of medicine, chemical and biological engineering, biomedical engineering, and materials science and engineering at Northwestern. He is among an elite group of scientists elected to all three branches of the U.S. National Academies — the National Academy of Sciences, the National Academy of Engineering and the National Academy of Medicine. He is a member of the American Academy of Arts and Sciences. Mirkin served on President Obama’s Council of Advisors on Science and Technology for eight years.

Congratulations to all of the winners in all of the categories!

As for the Norway announcement, it makes a bit of sense given that Fred Kavli was a Norwegian American. However, it’s a little hard to avoid the suspicion that there might be some regional and prize rivalry between Norway with its Kavli and Sweden its Nobel..

Celebrating the 20th Anniversary of the Authorization of the US 21st Century Nanotechnology Research and Development Act

The US National Nanotechnology Initiative (NNI) was signed into existence by then US President Bill Clinton in 2000 (one of his last official acts while still in office) but it was then US President George W. Bush who signed the 21st Century Nanotechnology Research and Development Act in 2003. My understanding is the act gave the NNI a more permanent status.

In any event it’s the 20th anniversary of the 2003 signing of the act as noted in a December 6, 2023 posting by : Lynn L. Bergeson and Carla N. Hutton on the National Law Review blog, Note: A link has been removed,

The White House Office of Science and Technology Policy (OSTP) and the National Nanotechnology Coordination Office (NNCO) announced on December 4, 2023, a series of events to drive U.S. leadership in nanotechnology, in celebration of the 20-year anniversary of the 21st Century Nanotechnology Research and Development Act. The announcement notes that for the past two decades, the National Nanotechnology Initiative (NNI) “has worked with more than 20 departments and agencies to advance a vision to understand and control matter at the nanoscale, for the benefit of society.” …

A December 4, 2023 White House Office of Science and Technology Policy (OSTP) news release announced the 20th anniversary and celebrations, Note: Links have been removed,

In celebration of the 20-year anniversary of the 21st Century Nanotechnology Research and Development Act, the White House Office of Science and Technology Policy (OSTP) and the National Nanotechnology Coordination Office (NNCO) are announcing a series of events to drive U.S. leadership in nanotechnology.

For the past two decades, the National Nanotechnology Initiative (NNI) has worked with more than 20 departments and agencies to advance a vision to understand and control matter at the nanoscale, for the benefit of society. Coordination across the government has allowed Americans to safely enjoy the benefits of nanotechnology, which has led to revolutions in technology and industry, including faster microchips, powerful mRNA vaccines, and clean energy technologies. Meanwhile, carbon nanotubes have improved the power and lifecycle of batteries; quantum dots make flat screen TVs more vibrant; and nanoparticles allow for faster medical diagnostics.

“Over the years, the NNI has dynamically and responsibly responded to the needs of the country,” said Dr. Branden Brough, Director of NNCO, which coordinates the NNI. “The initiative is a model for collaborative and thoughtful technology development, while supporting the rapid development of other emerging fields by creating the infrastructure and workforce development programs that bolster these growing industries.”

The NNI community will host a symposium on March 5, 2024 [emphasis mine] at the National Academies of Sciences, Engineering, and Medicine in Washington, D.C., to recognize the impact of research and development at the nanoscale and plan the NNI’s promising future. The event is open to the public. …

This week, as we celebrate the Act’s signing, the NNCO will release a series of reports and stories that illustrate the impact of the NNI. This includes readouts from the Nano4EARTH roundtable discussions [emphasis mine] about applying nanotechnology solutions to address climate change, such as surface technologies, new batteries and energy storage solutions, and greenhouse gas capture approaches. Also, the NNCO will highlight a new independent study [emphasis mine] about how the U.S. nanotechnology community contributes tens of billions of dollars—and potentially hundreds of billions of dollars—to the economy each year. And, to highlight the importance of this growing field, NNCO will feature the stories of early-career scientists who represent the promising future of nanotechnology.

Additional events will be held during the coming months, including science cafes across the country, activities at local museums, and podcasts and articles in the media. For more information about these activities, visit the NNI website.

The report/study

The independent study (Economic Impact Analysis: 20 Years of Nanotechnology Investments, 2002 – 2022) mentioned in the OSTP news release was launched on December 5, 2023 and highlighted here in a January 2, 2024 posting.

The symposium

Here’s a poster of the March 5, 2024 symposium celebrating the 20th anniversary of the act,

There’s a registration page where you can register for the in-person symposium and find more information about the speakers. I thought introduction and agenda from the registration page might be of interest, Note: A link has been removed,

Scientists and engineers across many fields and disciplines are united by their work at the nanoscale. Their diverse efforts have helped produce everything from faster microchips to powerful mRNA vaccines. The transformative impact of this work has been spurred by the coordination and focus on U.S. nanotechnology established by the 21st Century Nanotechnology Research and Development Act in 2003. Celebrating such a broad impact and envisioning the future can be quite challenging, but this event will bring together voices from across the emerging technology landscape. There will be experts who can speak on the importance of nanotechnology in quantum engineering, optics, EHS, plastics, DEIA, microelectronics, medicine, education, manufacturing, and more. We can’t predict what will emerge from this lively discussion between researchers, policymakers, members of industry, educators, and the public, but the conversation can only benefit from including more diverse perspectives – especially yours.

AGENDA

8:30-9:00   Coffee and refreshments

9:00-9:05   Welcome and Introduction

9:05-9:30   Policy Perspectives #1

9:30-10:15  Morning Keynote

10:15-10:45  Coffee Break

10:45-11:30  Panel: Responsible Development

11:30-12:15  Panel: Fundamental Research

12:15-1:15  Lunch, Poster Session, and Networking

1:15-1:45  Policy Perspectives #2

1:45-2:30  Keynote Panel: The Future of Nanotechnology

2:30-3:15  Panel: Workforce Development

3:15-3:45  Break

3:45-4:30  Panel: Infrastructure

4:30-5:15  Panel: Commercialization

5:15-6:00  Closing Keynote

6:00-7:00  Reception Sponsored by the Kavli Foundation

No details about exactly what is being discussed but it certainly seems like it will be a busy day.

Nano4EARTH

I found the OSTP news release a little confusing with regard to the “readouts from the Nano4EARTH roundtable discussions” but here’s how the Nano4EARTH (Climate Change National Nanotechnology Challenge) webpage describes its upcoming workshop and roundtables,

Nano4EARTH Kick-off Workshop

Click here for information about the Nano4EARTH Kick-off hybrid workshop, to be held in Washington, DC and online on Jan. 24–25, 2023.

Nano4EARTH Roundtable Discussions

The Nano4EARTH roundtable discussions aim to identify fundamental knowledge gaps, needs, and opportunities to advance current energy efficiency, sustainable development, and climate change goals. By convening stakeholders from different sectors, backgrounds, and expertise, the goals of these roundtables are to identify applicable lessons across the spectrum of technologies, discuss system-specific needs, scalability and commercialization challenges, and potential paths forward.

The topics of the roundtables were identified at the Nano4EARTH Kick-off Workshop as particularly promising areas that could have an impact in a short time frame (four years or less). 

Roundtables:

Coatings, Lubricants, Membranes, and Other Interface Technologies

Roundtable Information, Discussion Summary

Batteries and Energy Storage

Roundtable Information, Discussion Summary

Capture, Storage, and Use of Greenhouse Gases

Roundtable Information, Discussion Summary

Nano4EARTH Roundtable Discussion on Catalysts (January 24, 2024)

Roundtable Information

Other celebrations around the country

There’s this December 11, 2023 notice from the “Celebrating nanotechnology around the country” webpage on the NNI website,

In celebration of the 20-year anniversary of the signing of the 21st Century Nanotechnology Research and Development Act, which codified the National Nanotechnology Initiative, the National Nanotechnology Coordination Office is showing its appreciation for the many organizations across the country that have put together engagement events with the general public to raise awareness about nanotechnology.

Such events (compiled by the National Informal STEM Education (NISE) Network) include:

Nanotechnology Day Activities in Arizona

Family Science Nights in Greensboro, NC

Celebrating 45 Years of Nanoscale Research at the Cornell Nanoscale Science and Technology Facility

Twenty Years of Nanotechnology! Opportunity to engage your community with NanoDays activities

The end

Chad Mirkin at Northwestern University (Chicago, Illinois, US) who’s a pretty big deal in the nanomedicine field wrote an October 29, 2021 introductory essay for Scientific American,

A Big Bet on Nanotechnology Has Paid Off

The National Nanotechnology Initiative promised a lot. It has delivered more

We’re now more than two decades out from the initial announcement of the National Nanotechnology Initiative (NNI), a federal program from President Bill Clinton founded in 2000 to support nanotechnology research and development in universities, government agencies and industry laboratories across the United States. It was a significant financial bet on a field that was better known among the general public for science fiction than scientific achievement. Today it’s clear that the NNI did more than influence the direction of research in the U.S. It catalyzed a worldwide effort and spurred an explosion of creativity in the scientific community. And we’re reaping the rewards not just in medicine, but also clean energy, environmental remediation and beyond.

Before the NNI, there were people who thought nanotechnology was a gimmick. I began my research career in chemistry, but it seemed to me that nanotechnology was a once-in-a-lifetime opportunity: the opening of a new field that crossed scientific disciplines. In the wake of the NNI, my university, Northwestern University, made the strategic decision to establish the International Institute for Nanotechnology, which now represents more than $1 billion in pure nanotechnology research, educational programs and supporting infrastructure. Other universities across the U.S. made similar investments, creating new institutes and interdisciplinary partnerships.

He’s a little euphoric but his perspective and the information he offers is worth knowing about.

A view to controversies about nanoparticle drug delivery, sticky-flares, and a PNAS surprise

Despite all the excitement and claims for nanoparticles as vehicles for drug delivery to ‘sick’ cells there is at least one substantive problem, the drug-laden nanoparticles don’t actually enter the interior of the cell. They are held in a kind of cellular ‘waiting room’.

Leonid Schneider in a Nov. 20, 2015 posting on his For Better Science blog describes the process in more detail,

A large body of scientific nanotechnology literature is dedicated to the biomedical aspect of nanoparticle delivery into cells and tissues. The functionalization of the nanoparticle surface is designed to insure their specificity at targeting only a certain type of cells, such as cancers cells. Other technological approaches aim at the cargo design, in order to ensure the targeted release of various biologically active agents: small pharmacological substances, peptides or entire enzymes, or nucleotides such as regulatory small RNAs or even genes. There is however a main limitation to this approach: though cells do readily take up nanoparticles through specific membrane-bound receptor interaction (endocytosis) or randomly (pinocytosis), these nanoparticles hardly ever truly reach the inside of the cell, namely its nucleocytoplasmic space. Solid nanoparticles are namely continuously surrounded by the very same membrane barrier they first interacted with when entering the cell. These outer-cell membrane compartments mature into endosomal and then lysosomal vesicles, where their cargo is subjected to low pH and enzymatic digestion. The nanoparticles, though seemingly inside the cell, remain actually outside. …

What follows is a stellar piece featuring counterclaims about and including Schneider’s own journalistic research into scientific claims that the problem of gaining entry to a cell’s true interior has been addressed by technologies developed in two different labs.

Having featured one of the technologies here in a July 24, 2015 posting titled: Sticky-flares nanotechnology to track and observe RNA (ribonucleic acid) regulation and having been contacted a couple of times by one of the scientists, Raphaël Lévy from the University of Liverpool (UK), challenging the claims made (Lévy’s responses can be found in the comments section of the July 2015 posting), I thought a followup of sorts was in order.

Scientific debates (then and now)

Scientific debates and controversies are part and parcel of the scientific process and what most outsiders, such as myself, don’t realize is how fraught it is. For a good example from the past, there’s Leviathan and the Air-Pump: Hobbes, Boyle, and the Experimental Life (from its Wikipedia entry), Note: Links have been removed),

Leviathan and the Air-Pump: Hobbes, Boyle, and the Experimental Life (published 1985) is a book by Steven Shapin and Simon Schaffer. It examines the debate between Robert Boyle and Thomas Hobbes over Boyle’s air-pump experiments in the 1660s.

The style seems more genteel than what a contemporary Canadian or US audience is accustomed to but Hobbes and Boyle (and proponents of both sides) engaged in bruising communication.

There was a lot at stake then and now. It’s not just the power, prestige, and money, as powerfully motivating as they are, it’s the research itself. Scientists work for years to achieve breakthroughs or to add more to our common store of knowledge. It’s painstaking and if you work at something for a long time, you tend to be invested in it. Saying you’ve wasted ten years of your life looking at the problem the wrong way or have misunderstood your data is not easy.

As for the current debate, Schneider’s description gives no indication that there is rancour between any of the parties but it does provide a fascinating view of two scientists challenging one of the US’s nanomedicine rockstars, Chad Mirkin. The following excerpt follows the latest technical breakthroughs to the interior portion of the cell through three phases of the naming conventions (Nano-Flares, also known by its trade name, SmartFlares, which is a precursor technology to Sticky-Flares), Note: Links have been removed,

The next family of allegedly nucleocytoplasmic nanoparticles which Lévy turned his attention to, was that of the so called “spherical nucleic acids”, developed in the lab of Chad Mirkin, multiple professor and director of the International Institute for Nanotechnology at the Northwestern University, USA. These so called “Nano-Flares” are gold nanoparticles, functionalized with fluorophore-coupled oligonucleotides matching the messenger RNA (mRNA) of interest (Prigodich et al., ACS Nano 3:2147-2152, 2009; Seferos et al., J Am. Chem.Soc. 129:15477-15479, 2007). The mRNA detection method is such that the fluorescence is initially quenched by the gold nanoparticle proximity. Yet when the oligonucleotide is displaced by the specific binding of the mRNA molecules present inside the cell, the fluorescence becomes detectable and serves thus as quantitative read-out for the intracellular mRNA abundance. Exactly this is where concerns arise. To find and bind mRNA, spherical nucleic acids must leave the endosomal compartments. Is there any evidence that Nano-Flares ever achieve this and reach intact the nucleocytoplasmatic space, where their target mRNA is?

Lévy’s lab has focused its research on the commercially available analogue of the Nano-Flares, based on the patent to Mirkin and Northwestern University and sold by Merck Millipore under the trade name of SmartFlares. These were described by Mirkin as “a powerful and prolific tool in biology and medical diagnostics, with ∼ 1,600 unique forms commercially available today”. The work, led by Lévy’s postdoctoral scientist David Mason, now available in post-publication process at ScienceOpen and on Figshare, found no experimental evidence for SmartFlares to be ever found outside the endosomal membrane vesicles. On the contrary, the analysis by several complementary approaches, i.e., electron, fluorescence and photothermal microscopy, revealed that the probes are retained exclusively within the endosomal compartments.

In fact, even Merck Millipore was apparently well aware of this problem when the product was developed for the market. As I learned, Merck performed a number of assays to address the specificity issue. Multiple hundred-fold induction of mRNA by biological cell stimulation (confirmed by quantitative RT-PCR) led to no significant changes in the corresponding SmartFlare signal. Similarly, biological gene downregulation or experimental siRNA knock-down had no effect on the corresponding SmartFlare fluorescence. Cell lines confirmed as negative for a certain biomarker proved highly positive in a SmartFlare assay.  Live cell imaging showed the SmartFlare signal to be almost entirely mitochondrial, inconsistent with reported patterns of the respective mRNA distributions.  Elsewhere however, cyanine dye-labelled oligonucleotides were found to unspecifically localise to mitochondria   (Orio et al., J. RNAi Gene Silencing 9:479-485, 2013), which might account to the often observed punctate Smart Flare signal.

More recently, Mirkin lab has developed a novel version of spherical nucleic acids, named Sticky-Flares (Briley et al., PNAS 112:9591-9595, 2015), which has also been patented for commercial use. The claim is that “the Sticky-flare is capable of entering live cells without the need for transfection agents and recognizing target RNA transcripts in a sequence-specific manner”. To confirm this, Lévy used the same approach as for the striped nanoparticles [not excerpted here]: he approached Mirkin by email and in person, requesting the original microscopy data from this publication. As Mirkin appeared reluctant, Lévy invoked the rules for data sharing by the journal PNAS, the funder NSF as well as the Northwestern University. After finally receiving Mirkin’s thin-optical microscopy data by air mail, Lévy and Mason re-analyzed it and determined the absence of any evidence for endosomal escape, while all Sticky-Flare particles appeared to be localized exclusively inside vesicular membrane compartments, i.e., endosomes (Mason & Levy, bioRxiv 2015).

I encourage you to read Schneider’s Nov. 20, 2015 posting in its entirety as these excerpts can’t do justice to it.

The PNAS surprise

PNAS (Proceedings of the National Academy of Science) published one of Mirkin’s papers on ‘Sticky-flares’ and is where scientists, Raphaël Lévy and David Mason, submitted a letter outlining their concerns with the ‘Sticky-flares’ research. Here’s the response as reproduced in Lévy’s Nov. 16, 2015 posting on his Rapha-Z-Lab blog

Dear Dr. Levy,

I regret to inform you that the PNAS Editorial Board has declined to publish your Letter to the Editor. After careful consideration, the Board has decided that your letter does not contribute significantly to the discussion of this paper.

Thank you for submitting your comments to PNAS.

Sincerely yours,
Inder Verma
Editor-in-Chief

Judge for yourself, Lévy’s and Mason’s letter can be found here (pdf) and here.

Conclusions

My primary interest in this story is in the view it provides of the scientific process and the importance of and difficulty associated with the debates.

I can’t venture an opinion about the research or the counterarguments other than to say that Lévy’s and Mason’s thoughtful challenge bears more examination than PNAS is inclined to accord. If their conclusions or Chad Mirkin’s are wrong, let that be determined in an open process.

I’ll leave the very last comment to Schneider who is both writer and cartoonist, from his Nov. 20, 2015 posting,

LeonidSchneiderImagination

Insurance, nanotechnology, and risk

I’ve been meaning to do something on insurance and the nanotechnology industry for a while so I’m thankful to have stumbled across this July 15, 2013 article by Anya Khalamayzer, which concerns actuaries, for Property Casualty 360°,

“An emerging technology can leave insurers covering risks they never contemplated,” states the Casualty Actuarial Society (CAS) in a statement on this revolutionary occupation [nanotechnology].

Parr Schoolman, a CAS fellow and senior managing director at Aon Benfield, explains that despite the lack of definitive data on the nanotech industry, an actuary’s ability to analyze a situation can help insurers develop a product to cover a futuristic technology that has arrived on society’s doorstep.

“Working with limited data is exactly the area where actuaries add most value,” says Alex Krutov, president of Navigation Advisors, in an email to PC360. “In general, the ability to provide solid actuarial risk analysis can also help accelerate societal progress by making possible the development and introduction of new technologies and products that otherwise might be considered uninsurable and too risky.”

I find this bit from the article  interesting,

Krutov says, “Medical applications of nanotechnology are very promising.  At the same time, health and other risks of specific products based on nanotechnology have to be properly analyzed before any insurance underwriting decision is made.  While actuaries are not expected to be experts on nanotechnology or medicine, they provide the general framework for this risk analysis.”

It seems to me the only way a nonexpert could establish a general framework for risk analysis, as Krutov suggests, would be to read some of the literature and get reports from people who do have expertise. One has to wonder though, at what point a threshold, whatever it might be, is passed and something becomes insurable. For example, there’s Chad Mirkin’s therapeutic skin moisturizer breakthrough in July 2012, mentioned in my Penetrating the skin barrier posting,

Researchers at Northwestern University (Illinois, US) have found a way to deliver gene regulation technology using skin moisturizers. From the July 3, 2012 news item on Science Blog,

A team led by a physician-scientist and a chemist — from the fields of dermatology and nanotechnology — is the first to demonstrate the use of commercial moisturizers to deliver gene regulation technology that has great potential for life-saving therapies for skin cancers.

At what point, once the treatments have passed through clinical trials, does the treatment or the doctor giving the treatment become insurable? From the article,

Because nanotechnology has only been available since the 1984, and due to the cutting-edge speed at which it is being developed, reliable data describing its effects is often outdated. Furthermore, Kingdollar [Charlie Kingdollar, vice president and emerging issues officer of General Reinsurance Corporation] says more than 60 percent of firms and universities fail to conduct toxicity tests on nanomaterial.

According to the United States Environmental Protection Agency (EPA), nanomaterials are effective precisely because their size allows them to enter the body in ways not typically found in other chemicals: for example, through the blood-brain barrier or by crossing cell membranes.

Kingdollar appears to be suggesting uninsurability while at the same time noting possible future loopholes should companies insure some form of nanotechnology-enabled therapy or product.

A little digging unearthed this Dec. 17, 2012 news item on Nanowerk (Note: A link has been removed),

The article “Handling Nanotechnologies with foresight in the context of Liability insurance” (pdf), published by reinsurance company Gen Re, describes potential risks of nanotechnologies from the perspective of insurance companies and shows strategies for foresight handling.

The article concludes that “In summary it must be noted that our goal as an insurance industry should support highly profitable nanotechnologies from an underwriting perspective, but without losing sight of the considerable risk potential. This can only be achieved through risk identification, risk monitoring and risk analysis. Simply waiting until risk materialises could have significant consequences for the insurance industry.

… align both of those goals — support for nanotechnologies and justifiable limitation of the potential financial risks for the insurance industry. A step in the right direction could be to contain the problem of late claims, which are inherent with these technologies, by employing the claims made principle.”

While I find the jargon a little difficult, it does seem that another loophole is being developed in that last line about “employing the claims made principle.”

For further investigation, here’s a link to the 10 pp. article Handling Nanotechologies With Foresight in the Context of Liability Insurance by Richard Wieczorek for Gen Re.

 

Gloves, Québec’s (Canada) Institut de recherche Robert-Sauvé en santé et en sécurité du travail, and a workplace nanotoxicity methodology report

A new report on a workplace health and safety issue in regard to nanoparticles (Development of a Method of Measuring Nanoparticle Penetration through Protective Glove Materials under Conditions Simulating Workplace Use)  was released in June 2013 by Québec’s Institut de recherche Robert-Sauvé en santé et en sécurité du travail (IRSST). Little research has been done on exposure through skin (cutaneous exposure), most research has focused on exposure by inhalation according to the report (en français version here),

In the workplace, the main pathway to NP exposure is inhalation (Ostiguy et al., 2008a). Exposure by the cutaneous route has not been studied much, partly because of the widely held belief that skin offers an impermeable barrier to NPs (Truchon et al., 2008). Yet a growing number of studies have pointed to the possible percutaneous absorption of NPs, such as in the case of skin damaged by abrasion (Zhang et al., 2008), repeated flexion (Rouse et al., 2007) or even through intact skin (Ryman-Rasmussen et al., 2006). Pores, hair follicles and sweat glands may also play a role in facilitating absorption of NPs through the skin (Hervé-Bazin, 2007). The nanoparticles are then carried throughout the body by the lymphatic circulatory system (Papp et al., 2008). Induced direct toxic effects have also been reported for epidermal keratinocyte cells exposed to carbon nanotubes and other types of NPs (Shvedova, 2003). [p. 17 PDF version; p. 1 print version; Note: See report bibliography for citations]

The researchers examined gloves made of four different types of material: nitrile, latex, neoprene, and butyl rubber under a number of different conditions. One type of nanoparticle was used for the study, titanium dioxide in powder and liquid forms. The report summary provides a bit more detail about the decision to develop a methodology and the testing methods,

With the exponential growth in industrial applications of nanotechnologies and the increased risk of occupational exposure to nanomaterials, the precautionary principle has been recommended. To apply this principle, and even though personal protective equipment against nanoparticles must be considered only as a last resort in the risk control strategy, this equipment must be available. To respond to the current lack of tools and knowledge in this area, a method was developed for measuring the penetration of nanoparticles through protective glove materials under conditions simulating workplace use.

This method consists of an experimental device for exposing glove samples to nanoparticles in powder form or in colloidal solution, while at the same time subjecting them to static or dynamic mechanical stresses and conditions simulating the microclimate in the gloves. This device is connected to a data control and acquisition system. To complete the method, a sampling protocol was developed and a series of nanoparticle detection techniques was selected.

Preliminary tests were performed using this method to measure the resistance of four models of protective gloves of different thicknesses made of nitrile, latex, neoprene and butyl to the passage of commercial TiO2 nanoparticles in powder form or colloidal solution. The results seem to indicate possible penetration of the nanoparticles in some types of gloves, particularly when subjected to repeated mechanical deformation and when the nanoparticles are in the form of colloidal solutions. Additional work is necessary to confirm these results, and consideration should be given to the selection of the configurations and values of the parameters that best simulate the different possible workplace situations. Nevertheless, a recommendation can already be issued regarding the need for regular replacement of gloves that have been worn, particularly with the thinnest gloves and when there has been exposure to nanoparticles in colloidal solution.

For interested parties, here’s a citation for and a link to the report (PDF),

Development of a Method of Measuring Nanoparticle Penetration through Protective Glove Materials under Conditions Simulating Workplace Use by Dolez, Patricia; Vinches, Ludwig; Perron, Gérald; Vu-Khanh, Toan; Plamondon, Philippe; L’Espérance, Gilles; Wilkinson, Kevin; Cloutier, Yves; Dion, Chantal; Truchon, Ginette
Studies and Research Projects / Report  R-785, Montréal, IRSST, 2013, 124 pages.

I last wrote about gloves and toxicity in a June 11, 2013 posting about gloves with sensors (they turned blue when exposed to toxic levels of chemicals). It would be interesting if they could find a way to create gloves with sensors that warn you when you are reaching dangerous levels of exposure through your gloves. Of course, first they’d have to determine what constitute a dangerous level of exposure. The US National Institute of Occupational Health and Safety (NIOSH) recently released its recommendations for exposure to carbon nanofibers and carbon nanotubes (my April 26, 2013 posting). In layperson’s terms, the recommended exposure is close to zero exposure. Presumably, the decision was based on the principle of being ‘safe rather than sorry’.

One final comment about exposure to engineered nanoparticles through skin, to date there has been no proof that there has been any significant exposure via skin. In fact, the first significant breach of the skin barrier was achieved for medical research, Chad Mirkin and his team at Northwestern University trumpeted their research breakthrough (pun intended) last year, from my July 4, 2012 posting,

Researchers at Northwestern University (Illinois, US) have found a way to deliver gene regulation technology using skin moisturizers. From the July 3, 2012 news item on Science Blog,

A team led by a physician-scientist and a chemist — from the fields of dermatology and nanotechnology — is the first to demonstrate the use of commercial moisturizers to deliver gene regulation technology that has great potential for life-saving therapies for skin cancers.

The topical delivery of gene regulation technology to cells deep in the skin is extremely difficult because of the formidable defenses skin provides for the body. The Northwestern approach takes advantage of drugs consisting of novel spherical arrangements of nucleic acids. These structures, each about 1,000 times smaller than the diameter of a human hair, have the unique ability to recruit and bind to natural proteins that allow them to traverse the skin and enter cells.

This goes a long way to explaining why primary occupational health and safety research has focused on exposure via inhalation rather than skin.  That said, I think ensuring safety means minimizing exposure by all routes until more is known about the hazards.

DARPA (US Defense Advanced Research Projects Agency), nanoparticles, and your traumatized brain

According to the May 10, 2013 news item on Nanowerk,

DARPA, the U.S. Defense Advanced Research Projects Agency, has awarded $6 million to a team of researchers to develop nanotechnology therapies for the treatment of traumatic brain injury and associated infections.

Led by Professor Michael J. Sailor, Ph.D., from the University of California San Diego [UC San Diego], the award brings together a multi-disciplinary team of renowned experts in laboratory research, translational investigation and clinical medicine, including Erkki Ruoslahti, M.D., Ph.D. of Sanford-Burnham Medical Research Institute, Sangeeta N. Bhatia, M.D., Ph.D. of Massachusetts Institute of Technology and Clark C. Chen, M.D., Ph.D. of UC San Diego School of Medicine.

Ballistics injuries that penetrate the skull have amounted to 18 percent of battlefield wounds sustained by men and women who served in the campaigns in Iraq and Afghanistan, according to the most recent estimate from the Joint Theater Trauma Registry, a compilation of data collected during Operation Iraqi Freedom and Operation Enduring Freedom.

“A major contributor to the mortality associated with a penetrating brain injury is the elevated risk of intracranial infection,” said Chen, a neurosurgeon with UC San Diego Health System, noting that projectiles drive contaminated foreign materials into neural tissue.

The May 9, 2013 UC San Diego news release by Susan Brown, which originated the news item, describes the reasons why DARPA wants to use nanoparticles in therapies for people suffering from traumatic brain injury,

Under normal conditions, the brain is protected from infection by a physiological system called the blood-brain barrier. “Unfortunately, those same natural defense mechanisms make it difficult to get antibiotics to the brain once an infection has taken hold,” said Chen, associate professor and vice-chair of research in the Division of Neurosurgery at UC San Diego School of Medicine.

DARPA hopes to meet these challenges with nanotechnology. The agency awarded this grant under its In Vivo Nanoplatforms for Therapeutics program to construct nanoparticles that can find and treat infections and other damage associated with traumatic brain injuries.

“Our approach is focused on porous nanoparticles that contain highly effective therapeutics on the inside and targeting molecules on the outside,” said Sailor, the UC San Diego materials chemist who leads the team. “When injected into the blood stream, we have found that these silicon-based particles can target certain tissues very effectively.”

Several types of nanoparticles have already been approved for clinical use in patients, but none for treatment of trauma or diseases in the brain. This is due in part to the inability of nanoparticle formulations to cross the blood-brain barrier and reach their intended targets.

“Poor penetration into tissues limits the application of nanoparticles to the treatment of many types of diseases,” said Ruoslahti, distinguished professor at Sanford-Burnham and partner in the research. “We are trying to overcome this limitation using targeting molecules that activate tissue-specific transport pathways to deliver nanoparticles.”

There is another major hurdle for treating brain injuries (from the news release),

Treating brain infections is becoming more difficult as drug-resistant strains of viruses and bacteria have emerged. Because drug-resistant strains mutate and evolve rapidly, researchers must constantly adjust their approach to treatment.

In an attempt to hit this moving target, the team is making their systems modular, so they can be reconfigured “on-the-fly” with the latest therapeutic advances.

Nanocomplexes that contain genetic material known as short interfering RNA, or siRNA, developed by Bhatia’s research group at MIT, will be key to this aspect of the team’s approach.

“The function of this type of RNA is that it specifically intereferes with processes in a diseased cell. The advantage of RNA therapies are that they can be quickly and easily modified when a new disease target emerges,” said Bhatia, a bioengineering professor at MIT and partner in the research.

But effective delivery of siRNA-based therapeutics in the body has proven to be a challenge because the negative charge and chemical structure of naked siRNA makes it very unstable in the body and it has difficulty crossing into diseased cells. To solve these problems, Bhatia has developed nanoparticles that form a protective coating around siRNA.

“The nanocomplexes we are developing shield the negative charge of RNA and protect it from nucleases that would normally destroy it. Adding Erkki’s tissue homing and cell-penetrating peptides allows the nanocomplex to transport deep into tissue and enter the diseased cells,” she said.

Bhatia has previously used the cell-penetrating nanocomplex to deliver siRNA to a tumor cell and shut down its protein production machinery. Although her group’s effort has focused on cancer, the team is now going after two other hard-to-treat cell types: drug-resistant bacteria and inflammatory cells in the brain.

“The work proposed by this multi-disciplinary team should provide new tools to mitigate the debilitating effects of penetrating brain injuries and offer our warfighters the best chance of meaningful recovery,” Chen said. [emphasis mine]

BTW, the term ‘warfighters’ is new to me; are we replacing the word ‘soldier’?

Returning to the matter at hand, I found DARPA’s In Vivo Nanoplatforms for Therapeutics program which is described this way on its home page,

Disease limits soldier readiness and creates healthcare costs and logistics burdens. Diagnosing and treating disease faster can help limit its impact. [emphasis mine] Current technologies and products for diagnosing disease are principally relegated to in vitro (in the lab) medical devices, which are often expensive, bulky and fragile.

DARPA’s In Vivo Nanoplatforms (IVN) program seeks to develop new classes of adaptable nanoparticles for persistent, distributed, unobtrusive physiologic and environmental sensing as well as the treatment of physiologic abnormalities, illness and infectious disease.

The IVN Diagnostics (IVN:Dx) program effort aims to develop a generalized in vivo platform that provides continuous physiological monitoring for the warfighter. [emphasis mine] Specifically, IVN:Dx will investigate technologies that may provide:

  • Implantable nanoplatforms using bio-compatible and nontoxic materials
  • In vivo sensing of small and large molecules of biological interest
  • Multiplexed detection of analytes at clinically relevant concentrations
  • External interrogation of the nanoplatform free from any implanted communications electronics
  • Complete system demonstration in a large animal

The IVN Therapeutics (IVN:Tx) program effort will seek unobtrusive nanoplatforms for rapidly treating disease in warfighters.

(I see DARPA is using both soldier and warfighter’.)

This team is not the only one wishing to deliver drug therapies in a targeted fashion to the brain. My Feb. 19, 2013 posting mentioned Chad Mirkin (Northwestern University) and his team’s efforts with spherical nucleic acids (SNAs), from the posting,

Potential applications include using SNAs to carry nucleic acid-based therapeutics to the brain for the treatment of glioblastoma, the most aggressive form of brain cancer, as well as other neurological disorders such as Alzheimer’s and Parkinson’s diseases. Mirkin is aggressively pursuing treatments for such diseases with Alexander H. Stegh, an assistant professor of neurology at Northwestern’s Feinberg School of Medicine. (originally excerpted from this the Feb. 15, 2013 news release on EurekAlert)

Coincidentally, Mirkin has just been named ‘Chemistry World Entrepreneur of the Year’ by the UK’s Royal Society of Chemistry, from the May 10, 2013 news item on Nanowerk,

Northwestern University scientist Chad A. Mirkin, a world-renowned leader in nanotechnology research and its application, has been named 2013 Chemistry World Entrepreneur of the Year by the Royal Society of Chemistry (RSC). The award recognizes an individual’s contribution to the commercialization of research.

The RSC is honoring Mirkin for his invention of spherical nucleic acids (SNAs), new globular forms of DNA and RNA. These structures form the basis for more than 300 products commercialized by licensees of the technology.

I’m never quite sure what to make of researchers who receive public funding then patent and license the results of that research.

Getting back to soldiers/warfighters, I’m glad to see this research being pursued. Years ago, a physician mentioned to me that soldiers in Iraq were surviving injuries that would have killed them in previous conflicts. The problem is that the same protective gear which insulates soldiers against many injuries makes them vulnerable to abusive head trauma (same principle as ‘shaken baby syndrome’). For example, imagine having a high velocity bullet hit your helmet. You’re protected from the bullet but the impact shakes your head so violently, your brain is injured.

Chad Mirkin, spherical nucleic acids, and a new ‘periodic table’

There was a big splash in July 2012 with the announcement that Chad Mirkin’s team at Northwestern University (Chicago, Illinois) had devised a skin cream that penetrated the skin barrier to deliver medication (my July 4, 2012 posting),

A team led by a physician-scientist and a chemist — from the fields of dermatology and nanotechnology — is the first to demonstrate the use of commercial moisturizers to deliver gene regulation technology that has great potential for life-saving therapies for skin cancers.

The topical delivery of gene regulation technology to cells deep in the skin is extremely difficult because of the formidable defenses skin provides for the body. The Northwestern approach takes advantage of drugs consisting of novel spherical arrangements of nucleic acids. These structures, each about 1,000 times smaller than the diameter of a human hair, have the unique ability to recruit and bind to natural proteins that allow them to traverse the skin and enter cells.

Mirkin has just finished presenting (Feb. 15, 2013 and Feb. 17, 2013) more information about spherical nucleic acids and their implications at the AAAS  (American Association for the Advancement of Science) 2013 meeting in Boston, Massachusetts. From the Feb. 15, 2013 news release on EurekAlert,

Northwestern University’s Chad A. Mirkin, a world-renowned leader in nanotechnology research and its application, has invented and developed a powerful material that could revolutionize biomedicine: spherical nucleic acids (SNAs).

Potential applications include using SNAs to carry nucleic acid-based therapeutics to the brain for the treatment of glioblastoma, the most aggressive form of brain cancer, as well as other neurological disorders such as Alzheimer’s and Parkinson’s diseases. Mirkin is aggressively pursuing treatments for such diseases with Alexander H. Stegh, an assistant professor of neurology at Northwestern’s Feinberg School of Medicine.

“These structures are really quite spectacular and incredibly functional,” Mirkin said. “People don’t typically think about DNA in spherical form, but this novel arrangement of nucleic acids imparts interesting chemical and physical properties that are very different from conventional nucleic acids.”

Spherical nucleic acids consist of densely packed, highly oriented nucleic acids arranged on the surface of a nanoparticle, typically gold or silver.  [emphasis mine] The tiny non-toxic balls, each roughly 15 nanometers in diameter, can do things the familiar but more cumbersome double helix can’t do:

  • SNAs can naturally enter cells and effect gene knockdown, making SNAs a superior tool for treating genetic diseases using gene regulation technology.
  • SNAs can easily cross formidable barriers in the human body, including the blood-brain barrier and the layers that make up skin.
  • SNAs don’t elicit an immune response, and they resist degradation, resulting in longer lifetimes in the body.

“The field of medicine needs new constructs and strategies for treating disease,” Mirkin said. “Many of the ways we treat disease are based on old methods and materials. Nanotechnology offers the ability to rapidly create new structures with properties that are very different from conventional forms of matter.”

“We now can go after a whole new set of diseases,” Mirkin said. “Thanks to the Human Genome Project and all of the genomics research over the last two decades, we have an enormous number of known targets. And we can use the same tool for each, the spherical nucleic acid. We simply change the sequence to match the target gene. That’s the power of gene regulation technology.”

###

A member of President Obama’s Council of Advisors on Science and Technology, Mirkin is known for invention and development of biological and chemical diagnostic systems based upon nanomaterials. He is the inventor and chief developer of Dip-Pen Nanolithography, a groundbreaking nanoscale fabrication and analytical tool, and is the founder of four Chicago-based companies: AuraSense, AuraSense Therapeutics, Nanosphere and NanoInk.

Mirkin, in addition to his work with spherical nucleic acids, has been busy with other nanoparticles and possible dreams of a new ‘periodic table of elements’, from the Feb. 17, 2013 news release on EurekAlert,

Forging a new periodic table using nanostructures

Northwestern University’s Chad A. Mirkin, …, has developed a completely new set of building blocks that is based on nanoparticles and DNA. Using these tools, scientists will be able to build — from the bottom up, just as nature does — new and useful structures.

“We have a new set of building blocks,” Mirkin said. “Instead of taking what nature gives you, we can control every property of the new material we make. We’ve always had this vision of building matter and controlling architecture from the bottom up, and now we’ve shown it can be done.”

Using nanoparticles and DNA, Mirkin has built more than 200 different crystal structures with 17 different particle arrangements. Some of the lattice types can be found in nature, but he also has built new structures that have no naturally occurring mineral counterpart.

Mirkin can make new materials and arrangements of particles by controlling the size, shape, type and location of nanoparticles within a given particle lattice. He has developed a set of design rules that allow him to control almost every property of a material.

New materials developed using his method could help improve the efficiency of optics, electronics and energy storage technologies. “These same nanoparticle building blocks have already found wide-spread commercial utility in biology and medicine as diagnostic probes for markers of disease,” Mirkin added.

With this present advance, Mirkin uses nanoparticles as “atoms” and DNA as “bonds.” He starts with a nanoparticle, which could be gold, silver, platinum or a quantum dot, for example. The core material is selected depending on what physical properties the final structure should have.

He then attaches hundreds of strands of DNA (oligonucleotides) to the particle. The oligonucleotide’s DNA sequence and length determine how bonds form between nanoparticles and guide the formation of specific crystal lattices.

“This constitutes a completely new class of building blocks in materials science that gives you a type of programmability that is extraordinarily versatile and powerful,” Mirkin said. “It provides nanotechnologists for the first time the ability to tailor properties of materials in a highly programmable way from the bottom up.”

If I read these two news releases rightly, the process (nanoparticles as atoms and DNA as bonds), Mirkin uses to create new structures is the same process he has used to create spherical nucleic acids. Given Mirkin’s entrepreneurial inclinations, I am curious as to how many and what kind of patents might be ‘protecting’ this work.

Natural and engineered nanoparticles in an Orion magazine podcast & in a NanoBosc machinima piece

The Jan. 16, 2013 Orion magazine podcast discussion (more about that later) regarding safety and engineered and natural nanoparticles arose from an article (worth reading) by Heather Millar in the magazine’s January/February 2013 issue, Pandora’s Boxes.

For anyone familiar with the term ‘Pandora’s box’, Millar’s and the magazine’s bias is made clear immediately, nanoparticles are small and threatening. From the Pandora’s box Wikipedia essay,

Today, the phrase “to open Pandora’s box” means to perform an action that may seem small or innocuous, but that turns out to have severe and far-reaching consequences. [emphases mine]

Millar’s article is well written and offers some excellent explanations. For example, there’s this from Pandora’s Boxes,

So chemistry and physics work differently if you’re a nanoparticle. You’re not as small as an atom or a molecule, but you’re also not even as big as a cell, so you’re definitely not of the macro world either. You exist in an undiscovered country somewhere between the molecular and the macroscopic. Here, the laws of the very small (quantum mechanics) merge quirkily with the laws of the very large (classical physics). Some say nanomaterials bring a third dimension to chemistry’s periodic table, because at the nano scale, long-established rules and groupings don’t necessarily hold up.

Then, she has some dodgier material,

Yet size seems to be a double-edged sword in the nanoverse. Because nanoparticles are so small, they can slip past the body’s various barriers: skin, the blood-brain barrier, the lining of the gut and airways. Once inside, these tiny particles can bind to many things. They seem to build up over time, especially in the brain. Some cause inflammation and cell damage. Preliminary research shows this can harm the organs of lab animals, though the results of some of these studies are a matter of debate.

Some published research has shown that inhaled nanoparticles actually become more toxic as they get smaller. Nano–titanium dioxide, one of the most commonly used nanoparticles (Pop-Tarts, sunblock), has been shown to damage DNA in animals and prematurely corrode metals. Carbon nanotubes seem to penetrate lungs even more deeply than asbestos. [emphases mine]

I think it’s worth ‘unpacking’ these two paragraphs, so here goes.  Slipping past the body’s barriers is a lot more difficult than Millar suggests in the first paragraph. My July 4, 2012 posting on breakthough research  where they penetrated the skin barrier includes this comment from me,

After all the concerns  about nanosunscreens and nanoparticles penetrating the skin raised by civil society groups, the Friends of the Earth in particular, it’s interesting to note that doctors and scientists consider penetration of the skin barrier to be extremely difficult. Of course, they seem to have solved [as of July 2012] that problem which means the chorus of concerns may rise to new heights.

I had a followup in my Oct.3, 2012 posting titled, Can nanoparticles pass through the skin or not?, suggesting there’s still a lot of confusion about this topic even within the scientific community.

Moving on to the other ‘breaches’. As I recall, there was a recent  (Autumn 2012?) nanomedicine research announcement that the blood-brain barrier was breached by nanoparticles. I haven’t yet encountered any mention of breaching the gut and I mention lungs in my next paragraph where I discuss carbon nanotubes.

As for that second paragraph, it’s an example of scaremongering. ‘Inhaled nanoparticles become more toxic as their size decreases’—ok. Why mention nano-titanium oxide in pop tarts and sunblocks, which are not inhaled, in the followup sentence? As for the reference to DNA damage and corroded metals further on, this is straight out of the Friends of the Earth literature which often cites research in a misleading fashion including those two pieces.  There is research supporting part of Millar’s statement about carbon nanotubes—provided they are long and multiwalled. In fact, as they get shorter, the resemblance to asbestos fibers in the lungs or elsewhere seems to disappear as per my Aug 22, 2012 posting and my Jan. 16, 2013 posting.

You don’t need to read the article before listening to the fascinating Jan. 16, 2013 Orion magazine podcast with Millar (reading portions of her article) and expert guests, Mark Wiesner from Duke University and director of their Center for Environmental Implications of Nano Technology (CEINT was first mentioned in my April 15, 2011 posting), Ronald Sandler from Northeastern University and author of Nanotechnology: The Social And Ethical Issues, and Jaydee Hanson, policy director for the International Center for Technology Assessment.

The discussion between Wiesner, Sandler, and Hanson about engineered and natural nanoparticles is why I’ve called the podcast fascinating. Hearing these experts ‘fence’ with each other highlights the complexities and subtleties inherent in discussions about emerging technologies (nano or other) and risk. Millar did not participate in that aspect of the conversation and I imagine that’s due to the fact that she has only been researching this area for six months while the other speakers all have several years worth experience individually and, I suspect, may have debated each other previously.

At the risk of enthusing too much about naturally occurring nanoparticles, I’m mentioning, again (my Feb. 1, 2013 posting), the recently published book by Nanowiki, Nanoparticles Before Nanotechnology, in the context of the stunning visual images used to illustrate the book. I commented previously about them and Victor Puntes of the Inorganic Nanoparticles Group at the Catalan Institute of Nanotechnology (ICN) and one of the creators of this imagery, kindly directed me to a machinima piece (derived from the NanoBosc Second Life community) which is the source for the imagery. Here it is,

NanoBosc from Per4mance MetaLES ..O.. on Vimeo.

Happy Weekend!